부설판

용도

• Adjunctive therapy of chronic granulocytic leukemias or polycythemia vera
• Adjunctive therapy of chronic granulocytic leukemias or polycythemia vera

투여 방법

가능한 부작용

• Myelosuppression (anemia, leukopenia, thrombocytopenia)
• Pancytopenia (can take months to years for recovery)
• Bronchopulmonary dysplasia with pulmonary fibrosis (uncommon, chronic use)
• Uric acid nephropathy
• Stomatitis

주의사항 및 금기

• Patients with known hypersensitivity to busulfan
• Patients who have shown resistance to the drug in the past
• Pregnancy (FDA Category D), unless potential benefits outweigh the risks
• Nursing dams
• > **Warning**: Only veterinarians with the experience and resources to monitor the toxicity of this agent should administer this drug. * **Bone Marrow Depression**: The risk versus benefits of therapy must be carefully considered in patients with preexisting bone marrow depression or concurrent infections. * **Radiation Therapy**: Additive bone marrow depression may occur in patients undergoing concomitant radiation therapy. * **Teratogenicity**: Mutagenic in mice and may potentially cause a variety of fetal abnormalities. Avoid during pregnancy unless absolutely necessary.

약물 상호작용

• Acetaminophen: Use within 72 hours prior to busulfan can reduce busulfan clearance by reducing glutathione concentrations in tissues and blood.
• Cyclophosphamide: Can potentially reduce clearance of busulfan, probably by competing for available glutathione.
• Itraconazole: Potential decreased busulfan clearance.
• Myelosuppressant agents: Concurrent use with other bone marrow depressant medications may result in additive myelosuppression.
• Phenytoin: Possible increased clearance of busulfan.
• Thioguanine: Used concomitantly with busulfan may result in hepatotoxicity.

자주 묻는 질문